首页> 外文期刊>International journal of clinical practice >Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
【24h】

Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.

机译:大肠癌中细胞周期蛋白D1,E和细胞周期蛋白依赖性激酶抑制剂p21waf1 / cip1,p27kip1的表达模式:与其他细胞周期调节因子(pRb,p53和Ki-67和PC​​NA)的关系和临床病理特征。

获取原文
获取原文并翻译 | 示例
           

摘要

Aberrations in the cell cycle regulators are common features of many tumours and several have been shown to have prognostic significant in colorectal cancer. The expression patterns of cyclins D1 and E as well as cyclin-dependent kinase (CDK) inhibitors p21waf1/cip1 and p27kip1 and their interrelationship with other cell cycle checkpoint proteins [p53, pRb, Ki-67 and proliferative cell nuclear antigen (PCNA)] were investigated in colorectal cancer in order to ascertain coregulation and influence on tumour behaviour or survival. These molecular markers were localisated immunohistochemically using the monoclonal antibodies anticyclin D1 (DCS-6), anticyclin E (13A3), anti-p21 (4D10), anti-p27 (1B4), anti-p53 (DO7), anti-Rb (AB-5), MIB1 and PC10 in colorectal cancer tissue from 97 patients. Data were analysed statistically using the spss software program. Overexpression of cyclin D1, cyclin E and p21waf1/cip1 proteins (>5% positive neoplastic cells) was observed in 5.9%, 30% and 7.2% of the cases respectively. Increased levels of cyclin D1 (p = 0.0001) and p21waf1/cip1 protein (p = 0.03) in tumours with mucous differentiation were observed. Overexpression of cyclin D1 was correlated with tumour stage (p = 0.03), the lymph node involvement (p = 0.02), as well as p21waf1/cip1 protein expression (p < 0.0001). Cyclin E was positively correlated with p21waf1/cip1 (p = 0.014), as well as with the cell proliferation as measured by PCNA-labelling index (p = 0.011) and Ki-67 score (p = 0.007). A positive relationship of p21waf1/cip1 expression with the proliferative-associated index Ki-67 was noted (p = 0.005). Downregulation of p27kip1 was observed in 47.4% of the cases and was correlated with downregulation of pRb (p = 0.002) and PCNA score (p = 0.004). The prognostic significance of cyclins D1, E and CDK inhibitors p21waf1/cip1, p27kip1 in determining the risk of recurrence and overall survival with both univariate (long-rang test) and multivariate (Cox regression) methods of analysis showed no statistically significance differences. In conclusion, these findings suggest that, the levels of the cell cycle regulators studied, do not seems to have a prognostic value, in terms of predicting the risk of early recurrence and overall survival. In addition, the interrelationships, probably means their contribution to the regulation of cell growth, through different pathways in colorectal carcinogenesis.
机译:细胞周期调节因子的畸变是许多肿瘤的共同特征,并且已经显示几种在大肠癌中具有重要的预后意义。细胞周期蛋白D1和E以及细胞周期蛋白依赖性激酶(CDK)抑制剂p21waf1 / cip1和p27kip1的表达模式及其与其他细胞周期检查点蛋白[p53,pRb,Ki-67和增殖细胞核抗原(PCNA)的相互关系]为了确定共调节作用和对肿瘤行为或生存的影响,对结直肠癌进行了研究。使用单克隆抗体抗细胞周期蛋白D1(DCS-6),抗细胞周期蛋白E(13A3),抗p21(4D10),抗p27(1B4),抗p53(DO7),抗Rb(AB)免疫组织化学定位这些分子标记-5),来自97位患者的结直肠癌组织中的MIB1和PC10。使用spss软件程序对数据进行统计分析。分别在5.9%,30%和7.2%的病例中观察到细胞周期蛋白D1,细胞周期蛋白E和p21waf1 / cip1蛋白(> 5%阳性肿瘤细胞)的过表达。观察到具有粘液分化的肿瘤中细胞周期蛋白D1(p = 0.0001)和p21waf1 / cip1蛋白(p = 0.03)的水平升高。细胞周期蛋白D1的过表达与肿瘤分期(p = 0.03),淋巴结受累(p = 0.02)和p21waf1 / cip1蛋白表达相关(p <0.0001)。细胞周期蛋白E与p21waf1 / cip1(p = 0.014)以及通过PCNA标记指数(p = 0.011)和Ki-67评分(p = 0.007)测得的细胞增殖呈正相关。注意到p21waf1 / cip1表达与增殖相关指数Ki-67呈正相关(p = 0.005)。在47.4%的病例中观察到p27kip1的下调,并且与pRb(p = 0.002)和PCNA评分(p = 0.004)的下调相关。细胞周期蛋白D1,E和CDK抑制剂p21waf1 / cip1,p27kip1对单因素(长距离检验)和多因素(Cox回归)分析确定复发风险和总体生存的预后意义无统计学意义差异。总之,这些发现表明,所研究的细胞周期调节因子的水平在预测早期复发和整体生存的风险方面似乎没有预后价值。此外,相互关系可能意味着它们通过大肠癌发生过程中的不同途径对调节细胞生长做出了贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号